A Phase 3 interventional study of ADX-324 Dose Level 1 and ADX-324 Dose Level 2 in Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 and Hereditary Angioedema - Type 2, sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 48 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by ADARx Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 25th largest by planned enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 in phase 3, reaches primary completion later than 14 of the 17 other live ones, and was the 83rd registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
Ionis Pharmaceuticals, Inc. · Sites in United States, Australia, Italy and 2 more countries
Ages 2–11
Pharvaris Netherlands B.V. · Sites in United States, Australia, Austria and 13 more countries
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
ADARx Pharmaceuticals, Inc. · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 42 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 57 across the 74 interventional studies, 168 across the 7 observational. Of the 62 that completed or were terminated, 47 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 84 have an industry lead sponsor. The 10 most frequent:
ADARx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.
ADARx Pharmaceuticals, Inc. has 3 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
7 of the studies in Angioedemas, Hereditary with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: ADX-324 Dose Level 1
Drug: ADX-324 Dose Level 2
siRNA duplex oligonucleotide
siRNA duplex oligonucleotide
Safety of ADX-324 in Participants with HAE
Incidence and severity of treatment-emergent adverse events
Time frame: Month 36
Efficacy of ADX-324 in Preventing HAE Attacks
Number of Investigator-confirmed HAE attacks per month
Time frame: Month 36
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 50 months is above that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Onvuzosiran sodium
ADARx Pharmaceuticals, Inc.